Summary of IN8bio FY Conference Call (March 02, 2026) Company Overview - **Company**: IN8bio (NasdaqGM:INAB) - **Focus**: Development of gamma delta T cells as therapeutics for oncology and autoimmune diseases - **Expertise**: The company claims to be among the world's best in gamma delta T cell therapeutics, with a scientific co-founder having over 30 years of experience in the field [1][2] Clinical Programs - **Current Programs**: - INB-100: Focused on leukemia, specifically acute myeloid leukemia (AML) - INB-200 and INB-400: Genetically modified gamma delta T cell programs targeting solid tumors, with INB-200 focusing on glioblastoma - **Clinical Results**: - Patients in remission for over 4 years, particularly in severe cases of AML and glioblastoma [2][3] - **Pipeline Status**: - INB-300 and INB-500 programs are currently on hold due to capital constraints [4] Financials - **Recent Financing**: - Raised $40.2 million in December, with $20.1 million in the first tranche expected to last until the first half of 2027 [3] - **Future Funding**: A second tranche is contingent on achieving specific milestones later in the year [3][33] Treatment Approach - **Unique Strategy**: - Focus on reducing tumor mass to minimal residual disease before attacking remaining cells with gamma delta T cells, which are engineered to survive conventional chemotherapy [8][9] - **Dosing Strategy**: - Patients receive doses every 28 days, aiming to keep tumor cells static or reduce them over time [10][11] Clinical Data - **Patient Outcomes**: - Median progression-free survival for control patients was 6.6 months, while those receiving multiple doses had a median progression-free survival of 13 months and overall survival of 17.2 months [16][17] - **Statistical Significance**: - Data shows a direct correlation between the number of doses and survival rates, with a P value of less than 0.05 indicating statistical significance [20] T-Cell Engager Platform - **New Platform**: - INB-619 T cell engager platform aims to widen the therapeutic window and improve tolerability in autoimmune diseases [4][21] - **Challenges in Autoimmune Treatment**: - Current therapies often lead to lymphodepletion and associated risks, particularly for women of childbearing age [21][22] - **Innovative Design**: - The new T-cell engager targets both CD19 and gamma delta T cells, aiming to avoid common issues like cytokine release syndrome (CRS) [24][25] Competitive Landscape - **Market Position**: - IN8bio believes it is undervalued compared to competitors, citing its unique approach and promising clinical results [32] - **Head-to-Head Comparisons**: - Conducted experiments against FDA-approved drugs, demonstrating equivalent or superior B-cell depletion with a wider therapeutic window [27][28] Future Outlook - **Regulatory Path**: - Plans to seek FDA guidance based on current data, with potential for accelerated approval pathways [34] - **Upcoming Milestones**: - Anticipated updates on clinical data and animal model results later in the year [32][33] Conclusion - IN8bio is positioned as a leader in gamma delta T cell therapeutics, with promising clinical data and a unique approach to treating difficult cancers and autoimmune diseases. The company is actively seeking to advance its pipeline and regulatory strategy while addressing capital constraints.